Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi salmonellae

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 75-81

  Crump, John A ^a,b,c   Barrett, Timothy J ^a   Nelson, Jennifer T ^a   Angulo, Frederick J ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHROMOSOME MUTATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE FUNCTION; HUMAN; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLOSIS; SEROPREVALENCE; SEROTYPE; TREATMENT FAILURE; TYPHOID FEVER;

ANTI-INFECTIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; SALMONELLA TYPHI; TYPHOID FEVER;

EID: 0038573548     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375602     Document Type: Review

References (79)

1. World Health Organization. The world health report 1996: fighting disease, fostering development. Geneva: World Health Organization, 1996.
2. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607-25.
3. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-49.
4. Centers for Disease Control and Prevention. Typhoid fever: Mexico. MMWR Morb Mortal Wkly Rep 1972; 21:177-8.
5. Anderson ES. The problem and implication of chloramphenicol resistance in the typhoid bacillus. J Hyg (Lond) 1975; 74:289-99.
6. Paniker CKJ, Vilma KN. Transferable chloramphenicol resistance in Salmonella Typhi. Nature 1972; 239:109-10.
7. Threlfall EJ, Rowe B, Ward LR. Occurrence and treatment of multiresistant Salmonella Typhi in the UK. Public Health Laboratory Service Microbiology Digest 1991; 8:56-9.
8. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin Infect Dis 1997; 24:S106-9.
9. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 infections in the United States. New Engl J Med 1998; 338:1333-8.
10. Ackers M-L, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000; 283:2668-73.
11. NCCLS. Performance standards for antimicrobial susceptibility testing: thirteenth informational supplement. NCCLS document M100-S13 (M7). Wayne, PA: NCCLS, 2003.
12. Rowe B, Ward LR, Threlfall EJ. Ciprofloxacin-resistant Salmonella Typhi in the UK. Lancet 1995; 346:1302.
13. Rossiter S, McClellan J, Barrett T, Joyce K, Anderson AD. Emerging fluoroquinolone resistance among non-typhoidal Salmonella in the United States: NARMS, 1996-2000. NARMS Working Group. In: Centers for Disease Control and Prevention, ed. International Conference on Emerging Infectious Diseases. Atlanta: American Society for Microbiology Press, 2002:171-2.
14. Nakaya H, Yasuhara A, Yoshimura K, Oshihoi Y, Izumiya H, Watanabe H. Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica Typhimurium with mutations in both gyrA and parC. Emerg Infect Dis 2003; 9:255-7.
15. Chiu CH, Wu TL, Su LH, et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype Chloleraesuis. N Engl J Med 2002; 346:413-9.
16. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S. Ciprofloxacin-resistant Salmonella Typhi and treatment failure. Lancet 1999; 353: 1590-1.
17. Threlfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis 2001; 7:448-50.
18. Heurtin-Le Corre C, Donnio P-Y, Perrin M, Travert M-F, Avril J-L. Increasing incidence and comparison of nalidixic acid-resistant Salmonella enterica subsp enterica serotype Typhimurium isolates from humans and animals. J Clin Microbiol 1999; 37:266-9.
19. Isenbarger DW, Hoge CW, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002; 8:175-80.
20. Molbak K, Baggesen DL, Aarestrup FM, et al. An outbreak of multidrug resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med 1999; 341:1420-5.
21. Prats G, Mirelis B, Llovet T, Munoz C, Miro E, Navarro F. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob Agents Chemother 2000; 44: 1140-5.
22. Threlfall EJ, Ward LR, Rowe B. Increasing incidence of resistance to trimethoprim and ciprofloxacin in epidemic Salmonella Typimurium DT 104 in England and Wales. Eurosurveillance 1997; 2:81-4.
23. Threlfall EJ, Ward LR, Rowe B. Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Wales: the current situation. Clin Microbial Infect 1999; 5:130-4.
24. Molbak K, Gerner-Smidt P, Wegener HC. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg Infect Dis 2002; 8:514-5.
25. Helms M, Vastrup P, Gerner-Smidt P, Molbak K. Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium. Emerg Infect Dis 2002; 8:490-5.
26. Dutta P, Mitra U, Datta S, et al. Ciprofloxacin susceptible Salmonella Typhi with treatment failure. J Trop Pediatr 2001; 47:252-3.
27. Mehta A, Rodriques C, Joshi VR. Multiresistant Salmonella organisms in India. JAMA 1992; 267:1614.
28. Atkins BL, Gottlieb T. Emerging drug resistance and vaccination for typhoid fever. JAMA 1998; 279:579-80.
29. Chandel DS, Chaudhry R. Enteric fever treatment failures: a global concern. Emerg Infect Dis 2001; 7:762-3.
30. Umasankar S, Wall RA, Berger J. A case of ciprofloxacin-resistant typhoid fever. Commun Dis Rep CDR Rev 1992; 2:R139-40.
31. Nguyen Van J-C, Goldstein FW. Low-level resistance to fluoroquinolones among Salmonella and Shigella. Clin Microbiol Infect 2000; 6: 226-31.
32. Mitchell DH. Ciprofloxacin-resistant Salmonella Typhi: an emerging problem. Med J Aust 1997; 167:172.
33. Launay O, Nguyen Van J-C, Buu-Hoi A, Acar JF. Typhoid fever due to Salmonella Typhi strain of reduced susceptibility to fluoroquinolones. Clin Microbiol Infect 1997; 3:541-4.
34. Le Lostec Z, Fequeux S, Jouve P, Cheron M, Morner P, Boisivon A. Reduced susceptibility to quinolones in Salmonella Typhi acquired in Europe: a clinical failure of treatment. Clin Microbiol Infect 1997; 3: 576-7.
35. Dragsted UB, Pedersen P. Relapse of multiresistant Salmonella Typhi after combined therapy with ciprofloxacin and ceftriaxone. Clin Microbiol Infect 2000; 6:167-8.
36. Vasallo FJ, Martin-Rabadan P, Alcala L, Garcia-Lechuz JM, Rodriguez-Creixems M, Bouza E. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis 1998; 26:535-6.
37. McCarron B, Love WC. Acalculous nontyphoidal salmonellal cholecystitis requiring surgical intervention despite ciprofloxacin therapy: report of three cases. Clin Infect Dis 1997; 24:707-9.
38. Brown JC, Shanahan PM, Jesudason MV, Thomson CJ, Amyes SG. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella Typhi in India. J Antimicrob Chemother 1996; 37:891-900.
39. Ouabdesselam S, Tankovic J, Soussy CJ. Quinolone resistance mutations in the gyrA gene of clinical isolates of Salmonella. Microb Drug Resist 1996; 2:299-302.
40. Pers C, Sogaard P, Pallesen L. Selection of multiple resistance mutations in Salmonella enteritidis during treatment with ciprofloxacin. Scand J Infect Dis 1996; 28:529-31.
41. Piddock LJV, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella Typhimurium obtained from two patients. Antimicrob Agents Chemother 1993; 37:662-6.
42. Howard AJ, Joseph TD, Bloodworth LL, Frost JA, Chart H, Rowe B. The emergence of ciprofloxacin resistance in Salmonella Typhimurium. J Antimicrob Chemother 1990; 26:296-8.
43. Piddock LJV, Whale K, Wise R. Quinolone resistance in Salmonella: clinical experience. Lancet 1990; 335:1459.
44. Gibb AP, Lewin CS, Garden OJ. Development of quinolone resistance and multiple antibiotic resistance in Salmonella Bovismorbificans in a pancreatic abscess. J Antimicrob Chemother 1991; 28:318-21.
45. Boswell TC, Coleman DJ, Purser NJ, Cobb RA. Development of quinolone resistance in Salmonella: failure to prevent splenic abscess. J Infect 1997; 34:86-7.
46. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp? Antimicrob Agents Chemother 2003; 47:827-9.
47. Herikstad H, Hayes P, Mokhtar M, Fracaro ML, Threlfall EJ, Angulo FJ. Emerging quinolone-resistant Salmonella in the United States. Emerg Infect Dis 1997; 3:371-2.
48. Sorensen TL, Blom M, Monnet DL, Frimodt-Moller N, Poulsen RL, Espersen F. Transient intestinal carriage after ingestion of antibiotic-resistant Enterococcus faecium from chicken and pork. N Engl J Med 2001; 345:1161-6.
49. Crump JA, Griffin PM, Angulo FJ. Bacterial contamination of animal feed and its relationship to human foodborne illness. Clin Infect Dis 2002; 35:859-65.
50. White DG, Zhao S, Sudler R, et al. The isolation of antibiotic-resistant Salmonella from retail ground meats. N Engl J Med 2001; 345:1147-54.
51. Gorbach SL. Antimicrobial use in animal feed: time to stop. N Engl J Med 2001; 345:1202-3.
52. Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, Swartz MN. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother 1989; 33:283-90.
53. Okazaki T, Hirai K. Cloning and nucleotide sequence of the Pseudomona aeruginosa nfxB gene, conferring resistance to new quinolones. FEMS Microbiol Lett 1992; 76:197-202.
54. Yoshida H, Bogaki M, Nakamura S. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172:6942-9.
55. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:1973-8.
56. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797-9.
57. Tran JH, Jacoby GA. Mechanisms of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99:5638-42.
58. Webber M, Piddock LJV. Quinolone resistance in Escherichia coli. Vet Res 2001; 32:275-84.
59. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991; 26:335-75.
60. Wain J, Hoa NTT, Chinh NT, et al. Quinolone-resistant Salmonella Typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404-10.
61. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999; 37:3572-7.
62. Knudsen JD, Skov RL, Gerner-Smidt P, Pallesen LV, Frimodt-Moller N. Lack of effect of ciprofloxacin against Salmonella Typhimurium DT104 with MICs within NCCLS breakpoint [abstract A-2091]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society of Microbiology Press, 2001:596.
63. Brown JC, Thomson CJ, Amyes SGB. Mutations of the gyrA gene of clinical isolates of Salmonella Typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J Antimicrob Chemother 1996; 37:351-6.
64. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
65. Craig WA. Does dose matter? Clin Infect Dis 2001; 33(Suppl 3):S233-7.
66. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-92.
67. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intraveous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
68. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-60.
69. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intraveous antibiotics. Am J Med 1991; 91:462-70.
70. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2:378-424.
71. Knapp JS, Hale JA, Neal SW, Wintersheild K, Rice RJ, Whittington WL. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 1995; 39: 2442-5.
72. Klugman KP. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin Infect Dis 2003; 36:783-5.
73. Smith MD, Duong NM, Hoa NTT, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994; 38:1716-20.
74. Hien TT, Bethell DB, Hoa NTT, et al. Short course ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995; 20:917-23.
75. Duong NM, Chau NVV, Anh DCV, et al. Short course ofloxacin in the treatment of typhoid fever. JAMA (Southeast Asia) 1995; 11:21-5.
76. Vinh H, Wain J, Hanh VTN, et al. Two or three days of ofloxacin treatment for uncomplicated multi-drug resistant typhoid fever in children. Antimicrob Agents Chemother 1996; 40:958-61.
77. Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996; 74:44-6.
78. Butler T, Sridhar CB, Daga MK, et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 1999; 44:243-50.
79. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999; 43:1441-4.